Lonza - PBMCs

EDITORIAL SECTION

KNOWLEDGE BANK

  • Articles

    Mass Spectrometers: Principles, Instrumentation, Applications, and Future Perspectives

    Mass spectrometry MS is one of the most powerful analytical technologies available in modern science It enables the identification characterization and quantification of compounds based on their masstocharge ratio mz Since its development in the early twentieth century mass spectrometry has evolved from a basic analytical tool into a sophisticated technology capable of studying highly complex biol...

TOP ARTICLES

  • 1

    Decentralization - The Future of Clinical Trials

    Nikhila Shashikanth

    Decentralized clinical trials (DCTs) leads with a premise to leverage technology to transform the traditional clinical trials model. Incorporating digital tools, telemedicine, and real-world data, DCT...

press releasesRead more...

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US FacebookPinterest

Invagen Pharmaceuticals Inc a wholly owned subsidiary of Cipla Limited BSE NSE CIPLA today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co Ltd

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

Fresenius Kabi a global healthcare company part of the Fresenius Group specializing in lifesaving therapies and technologies today announced the US launch of the FDAapproved generic Sugammadex

Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia

Lkahi Therapeutics a subsidiary of Glucotrack Inc Nasdaq GCTK today announced the continued participation of the University of Georgias Student Industry Fellows Program in the ai Futures Lab

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock NASDAQ SRRK a global biopharmaceutical company dedicated to improving the lives of patients with rare severe and debilitating neuromuscular diseases by applying its worldleading platform

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

09 - 10

Sep 2026

iPSC Drug Development Summit

Hyatt Regency Boston Harbour,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

LATEST NEWSRead more...

FDA Approves First Drug to Treat Alexander Disease

The US Food and Drug Administration FDA has approved Zanvastro zilganersen injection for the treatment of Alexander disease in paediatric and adult patients It is the first FDAapproved treatment

AbbVie Completes Acquisition of Apogee Therapeutics

AbbVie has completed its acquisition of Apogee Therapeutics bringing the biotechnology company and its pipeline of antibodybased treatments into AbbVie

EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

EpiVax Inc has launched AIenhanced features for ISPRI its in silico platform for assessing the immunogenicity risk of biotherapeutics The update includes an improved JanusMatrix model

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader

Thermo Fisher Scientific has launched the Thermo Scientific Multiskan Ease Absorbance Microplate Reader designed to simplify routine laboratory analysis involving proteins cells and microorganisms

Juniper Biosciences Receives FDA Breakthrough Therapy Designation for JBS-003

Juniper Biosciences has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for JBS Ffluoromisonidazole or FMISO a hypoxia tracer being developed to guide reduced radiation therapy in patients with HPVpositive oropharyngeal carcinoma OPC

FDA approves PharmaEssentia’s BESREMi for adults with essential thrombocythaemia

PharmaEssentia USA Corporation a subsidiary of PharmaEssentia Corporation has received approval from the US Food and Drug Administration FDA for BESREMi ropeginterferon alfabnjft to treat adults with essential thrombocythaemia ET a rare form of blood cancer